Liver injury and recovery following radiation therapy for hepatocellular carcinoma: insights from functional liver imaging

2024-9-9

Oncologic outcomes and rates of hepatotoxicity following stereotactic body radiotherapy for hepatocellular carcinoma

2024-9-7

Minimally invasive surgery approaches in major liver resection for hepatocellular carcinoma

2024-8-26

The role of immune checkpoint inhibitors and/or Yttrium-90 radioembolization in the management of hepatocellular carcinoma: challenges of treatment sequence

2024-8-21

Glioma-associated oncogene (GLI)-specific decoy oligodeoxynucleotide induces apoptosis and attenuates proliferation, colony formation, and migration in liver cancer cells

2024-7-30

Multidisciplinary assessment of tumor response after internal and external radiation therapy for hepatocellular carcinoma

2024-7-24

Interpretation of the updates of the chinese guidelines for the diagnosis and treatment of primary liver cancer (CNLC-2024 Edition)

2024-7-17

Hepatic arterial infusion chemotherapy: a review with technical notes

2024-7-7

Measures for response assessment in HCC treatment

2024-7-4

Pneumonia promotes pulmonary metastasis of HCC after transplantation via VEGF regulated PI3K/AKT/Cas-9 signaling and angiogenesis

2024-6-24

RNA-based therapies in hepatocellular carcinoma: state of the art and clinical perspectives

2024-6-20

Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian treatment guidelines

2024-5-30

Emerging data on immune checkpoint inhibitors in the neoadjuvant and adjuvant setting for patients with hepatocellular carcinoma

2024-4-28

Shedding light on the role of LAG-3 in hepatocellular carcinoma: unraveling immunomodulatory pathways

2024-4-26

Impact of diet and gut microbiota changes in the development of hepatocellular carcinoma

2024-4-24

Lymphatic spread from left-sided intrahepatic cholangiocarcinoma: reconsiderations based on the lymphatic drainage from the liver

2024-4-23

Achieving SVR in patients with hepatitis C-related HCC is associated with an improvement in overall survival: real word data

2024-4-22

MASLD-mimicking microenvironment drives an aggressive phenotype and represses IDH2 expression in hepatocellular carcinoma

2024-4-7

Progression of liver disease and associated risk of hepatocellular carcinoma

2024-3-28

Reflections and perspectives on adjuvant treatment in the setting of resected hepatocellular carcinoma

2024-3-20

Introduction to 2023 Chinese expert consensus on the whole-course management of hepatocellular carcinoma

2024-3-20

Chinese expert consensus on composite ablation system for the treatment of primary liver cancer (2023 edition)

2024-3-14

Introduction of Chinese expert consensus on neoadjuvant therapy for primary liver cancer (2023 edition)

2024-3-12

Advancements in hepatocellular carcinoma diagnosis and treatment: liquid biopsy and surgical as precision treatment

2024-2-21

Introduction of the Chinese expert consensus on postoperative adjuvant therapy for hepatocellular carcinoma (2023 Edition)

2024-1-24

Racial, ethnic, and socioeconomic differences in hepatocellular carcinoma across the United States

2024-1-18

Precise staging of advanced HCC promotes higher quality of personalized treatment management: Chinese experts consensus on precision diagnosis and management of advanced hepatocellular carcinoma (2023)

2024-1-15

Interpretation of Chinese expert consensus on the whole-course management of hepatocellular carcinoma (2023 edition)

2024-1-12

Mutation-based therapies for intrahepatic cholangiocarcinoma: new options on the horizon

2024-1-12

Crosstalk between cancer cell plasticity and immune microenvironment in cholangiocarcinoma

2024-1-9

Dysmetabolic comorbidities and non-alcoholic fatty liver disease: a stairway to metabolic dysfunction-associated steatotic liver disease

2024-1-1

Role of temporary portosystemic surgical shunt during liver resection to prevent a post-resection small for size-like syndrome

2024-1-1

Associations between physical activity and risk of liver cancer: results from a population-based cohort study in Chinese women

2024-1-1

The role of percutaneous hepatic perfusion (PHP) in the treatment of cholangiocarcinoma

2024-1-1

Challenges and opportunities for treating intrahepatic cholangiocarcinoma: targeted therapy

2023-12-31

MASLD co-aggregates with HCC in families-names change, fa(c)ts remain

2023-12-29

Hepatic venous pressure gradient in hepatic resection for hepatocellular carcinoma

2023-11-21

Targeted mutation-based therapy for intrahepatic cholangiocarcinoma

2023-11-15

The tumor microenvironment in hepatocarcinoma: dissecting the functions of cancer-associated fibroblasts

2023-11-3

The role of exosomes in therapeutic resistance of hepatocellular carcinoma

2023-10-30

Treatment of intrahepatic cholangiocarcinoma: evidence for the role of percutaneous ablation

2023-10-24

Trans-arterial chemoembolization and radioembolization for treatment of intrahepatic cholangiocarcinoma

2023-10-12

Angiogenesis: the Yin and Yang in intrahepatic cholangiocarcinoma

2023-8-23

Advanced and emerging radiation therapy approaches for intrahepatic cholangiocarcinoma

2023-8-18

The role of gut microbiome and fecal microbiota transplantation in liver cancer and related complications: mechanisms and therapeutic potentials

2023-8-10

Review of IDH mutations and potential therapies for intrahepatic cholangiocarcinoma

2023-8-3

Perspective of tumor heterogeneity for treatments of intrahepatic cholangiocarcinoma with intrahepatic lithiasis

2023-8-1

Insights on liver transplantation and multimodal treatment for intrahepatic cholangiocarcinoma

2023-8-1

Neoadjuvant chemotherapy alone or combined with trans-arterial therapies for downstaging unresectable intrahepatic cholangiocarcinoma to surgical resection: a narrative review

2023-7-20

Cholangiocarcinoma tumor microenvironment highlighting fibrosis and matrix components

2023-7-13